ct
also
major
role
monitor
diseas
progress
evalu
efficaci
treatment
new
potenti
therapi
current
investig
multipl
trial
worldwid
tocilizumab
recent
demonstr
effect
patient
sever
pneumonia
report
favor
chang
ct
find
man
receiv
tocilizumab
treatment
pneumonia
man
without
signific
clinic
histori
initi
present
syncop
vital
sign
within
normal
rang
ear
temperatur
oxygen
satur
room
air
chest
xray
show
mild
linear
densiti
lower
middl
left
lung
field
laboratori
investig
show
increas
white
blood
cell
count
per
elev
serum
lactat
level
ul
elev
reactiv
c
protein
rcp
mgdl
blood
test
show
normal
result
detect
throat
swab
sampl
rtpcr
due
worsen
blood
test
day
white
blood
cell
count
per
lactat
ul
crp
mgdl
patient
admit
dedic
ward
day
patient
develop
dyspnea
decreas
oxygen
satur
increas
crp
observ
mgdl
white
blood
cell
count
per
ngl
normal
valu
ngdl
day
unenhanc
chest
ct
show
presenc
diffus
bilater
air
space
opac
includ
ground
glass
opac
consolid
preval
posterior
distribut
linear
opac
mainli
peripher
mild
bilater
pleural
effus
mediastin
lymphadenopathi
figur
assist
ventil
start
patient
receiv
dose
tocilizumab
mgkg
hour
apart
day
day
crp
drop
mgdl
white
blood
cell
count
per
patient
clinic
condit
progress
improv
ventilatori
support
gradual
wean
day
repeat
chest
ct
show
mark
improv
ct
find
size
reduct
air
cell
opac
densiti
reduct
consolid
evid
ground
glass
opac
peripher
reticular
opac
reduct
pleural
effus
mediastin
lymphadenopathi
tocilizumab
human
recombin
monoclon
antibodi
act
receptor
antagonist
provid
clinic
benefit
studi
chines
patient
sever
pneumonia
therefor
italian
medicin
agenc
aifa
announc
march
launch
independ
phase
studi
assess
efficaci
safeti
monoclon
antibodi
treatment
pneumonia
scenario
chest
ct
play
central
role
differ
studi
demonstr
import
chest
ct
diagnosi
first
assess
pneumonia
demonstr
damag
lung
parenchyma
includ
interstiti
inflamm
consolid
similar
featur
previous
report
coronaviru
infect
howev
data
current
avail
chang
chest
ct
find
initi
diagnosi
patient
recoveri
evalu
therapeut
efficaci
like
near
futur
chest
ct
becom
pivot
tool
monitor
diseas
progress
effect
experiment
therapi
patient
affect
pneumonia
author
declar
conflict
interest
relat
articl
author
fulli
particip
studi
approv
final
draft
man
receiv
tocilizumab
treatment
pneumonia
unenhanc
ct
imag
lung
transvers
plane
obtain
day
show
diffus
air
space
opac
mainli
consolid
poorli
repres
ground
glass
opac
distribut
bilater
predomin
posterior
locat
linear
opac
bilater
even
evid
left
side
diffus
thicken
bronchial
wall
present
well
mild
bilater
pleural
effus
b
mediastin
window
unenhanc
ct
imag
show
mediastin
lymphadenopathi
arrow
c
unenhanc
ct
imag
lung
transvers
plane
obtain
day
show
mark
improv
ct
find
bilater
reduct
consolid
ground
glass
opac
still
visibl
predomin
peripher
posterior
locat
peripher
linear
stripe
opac
visibl
mediastin
window
unenhanc
ct
imag
show
mild
decreas
size
lymphadenopathi
